Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 88 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2016', provides in depth analysis on Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted pipeline therapeutics. 

The report provides comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) 
- The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7

Introduction 8
Global Markets Direct Report Coverage 8
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Overview 9
Therapeutics Development 10
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Products under Development by Stage of Development 10
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Products under Development by Therapy Area 11
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Products under Development by Indication 12
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Products under Development by Companies 16
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Products under Development by Universities/Institutes 19
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment 21
Assessment by Monotherapy/Combination Products 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development 26
Addex Therapeutics Ltd 26
Bristol-Myers Squibb Company 27
Eisai Co., Ltd. 28
Eli Lilly and Company 29
Heptares Therapeutics Limited 30
Hua Medicine (Shanghai) Ltd. 31
Johnson & Johnson 32
Medgenics, Inc. 33
Merz Pharma GmbH & Co. KgaA 34
Sumitomo Dainippon Pharma Co., Ltd. 35
Toray Industries, Inc. 36
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles 37
alloswitch-1 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
BMS-952048 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
BMS-955829 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
dipraglurant ER - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
dipraglurant IR - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
DSR-98776 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
fasoracetam - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
GET-73 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
HTL-14242 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
JNJ-46778212 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
LSN-2463359 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
LSN-2814617 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
remeglurant - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule to Antagonize mGlu5 for Pain - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecule to Antagonize mGluR5 for CNS Disorders - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
VU-0092273 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
VU-0431316 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
VU-0463841 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
VU-0467558 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Projects 67
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products 71
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Featured News & Press Releases 73
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD 73
Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society 73
Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers 74
Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers 76
Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept 77
Jan 04, 2016: Addex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease 78
Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial 78
Aug 14, 2015: Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson's Disease 79
Jul 22, 2015: Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation 80
Feb 23, 2015: Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation 81
Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia 82
Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 82
May 01, 2013: Addex's Dipragluant Demonstrates Dose-dependent mGlu5 Receptor Occupancy In Non-human Primate PET Study 83
Apr 22, 2013: Addex Obtains European Composition Of Matter Patent Covering Dipraglurant And Other mGlu5 Negative Allosteric Modulators 85
Apr 18, 2013: Addex's Dipraglurant Normalizes Striatal Cholinergic Dysfunction In Validated Preclinical Model Of Primary Generalized Torsion Dystonia 1 85

Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88

List of Tables

Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Assessment by Monotherapy/Combination Products, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 25
Pipeline by Addex Therapeutics Ltd, H2 2016 26
Pipeline by Bristol-Myers Squibb Company, H2 2016 27
Pipeline by Eisai Co., Ltd., H2 2016 28
Pipeline by Eli Lilly and Company, H2 2016 29
Pipeline by Heptares Therapeutics Limited, H2 2016 30
Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 31
Pipeline by Johnson & Johnson, H2 2016 32
Pipeline by Medgenics, Inc., H2 2016 33
Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 34
Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 35
Pipeline by Toray Industries, Inc., H2 2016 36
Dormant Projects, H2 2016 67
Dormant Projects (Contd..1), H2 2016 68
Dormant Projects (Contd..2), H2 2016 69
Dormant Projects (Contd..3), H2 2016 70
Discontinued Products, H2 2016 71
Discontinued Products (Contd..1), H2 2016 72